Contact Us

Oral Osteoporosis Drug Side Effects Esophageal Cancer Risk
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Were you diagnosed with Esophogeal Cancer?

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bisphosphonates-Esophageal Cancer

oral ostepororsis, esophogeal cancer risk, side effects, lawsuits

Oral Osteoporosis, Bisphosphonates Drugs, Esophageal Cancer Side Effects Lawsuits

Oral Osteoporosis Drugs, Esophageal Cancer Risk, Throat, Oral Cancer, Side Effects, Lawsuits | Bisphosphonates, Fosamax, Actonel, Boniva, Atelvia, Didronel, Skelid, FDA Warning

Bisphosphonates-Esophageal Cancer

Have you been diagnosed with esophageal cancer while taking oral bisphosphonates such as, - Fosamax, Actonel, Boniva, Atelvia, Didronel, or Skelid - for osteoporosis? The U.S. Food & Drug Administration (FDA) is currently conducting an ongoing safety review of oral osteoporosis drugs (bisphosphonates) of a possible link to esophageal cancer, a serious form of cancer that could be a side effect of oral bisphosphonate use.

The defective drug lawyers at Parker Waichman LLP are investigating potential lawsuits on behalf of esophageal cancer victims and other oral bisphosphonate side effects. If you or someone you care about developed esophageal cancer that might be associated with one of these drugs, you may be able to obtain compensation for your medical bills, lost wages, and pain and suffering by filing a bisphosphonate esophageal cancer lawsuit. To learn how our personal injury lawyers can help you, please contact us today.

Oral Bisphosphonates and Esophogeal Cancer Risk

Oral bisphosphonates include the drugs Fosamax, Actonel, Boniva, Atelvia, Didronel, and Skelid. Oral bisphosphonates are used for the prevention and treatment of osteoporosis, a disease that makes bones weak and prone to break, as well as other bone diseases such as Paget's disease. One side effect of oral bisphosphonates is irritation of the esophagus, which can lead to esophagitis or esophageal ulcers, which may bleed.

The FDA is currently reviewing data from published studies to evaluate whether use of oral bisphosphonates is associated with an increased risk of esophageal cancer. According to a Drug Safety Communication issued by the agency on July 21, 2011, studies linking oral bisphosphonates to the development of esophageal cancer have been inconclusive so far. One of the largest studies reviewed by the FDA, a British study published in 2010, found that people taking oral bisphosphonates for more than five years may be doubling their risk of developing esophageal cancer. However, a second large study that drew data from the same British database found no increased risk.

In its communication, the FDA said it is unable to draw conclusions regarding the association between oral bisphosphonates and esophageal cancer, and for now, the agency continues to believe their benefits outweigh their risks.

Need Legal Help Regarding Bisphosphonates Side Effects?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



Bisphosphonates-Esophageal CancerRSS Feed

New Lawsuit Alleges that Fosamax Caused Femur Fractures in Both Thighs

Sep 18, 2012 | Parker Waichman LLP
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Fosamax caused a femur fracture. The suit was filed on August 30th in the Superior Court of New Jersey Law Division, Atlantic County (Docket No. ATL-L-6104-12 MT). Merck Sharp & Dohme Corp. and Merck & Co., Inc. have been named as Defendants. According to the Complaint, the Plaintiff began taking Fosamax in October 2000. Thereafter, she...

Bisphosphonates, Dental Procedures Not a Good Combo for Some Cancer Patients

Sep 13, 2012 | Parker Waichman LLP
New research suggests that people taking bisphosphonate drugs in the treatment of cancers multiple myeloma or Waldenstrom's macroglobulinemia are more likely to suffer osteonecrosis of the jaw (ONJ) after they undergo a dental procedure.  According to a report on a new study from scientists at Ospedale Nuovo Regina Margherita in Rome, Italy, nearly 80 percent of the cases of ONJ observed as part of the study were among people who had recently undergone a dental surgery,...

After Suffering Two Femur Fractures While Taking Fosamax, Indiana Woman Files Lawsuit Alleging Fosamax Caused Both Bone Breaks

Jul 16, 2012 | Parker Waichman LLP
Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral bisphosphonate. According to the FDA, bisphosphonates may not provide any long-term benefits while simultaneously increasing the risk of atypical femur fractures. Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a Fosamax lawsuit naming Merck Sharp & Dohme Corp.,...

New Study Finds Link between Fosamax, Other Bone Drugs and Esophageal Cancer

May 31, 2012 | Parker Waichman LLP
A new study has found there have been more reports of esophageal cancer associated with Fosamax and other bisphosphonates than had been previously thought.  The study, which is to be presented this week at the  annual meeting of the American Society of Clinical Oncology, found that 128 cases of esophageal cancer associated with the use of bisphosphonates had been reported to the U.S. Food & Drug Administration's (FDA) adverse event reporting database, most of which were reported...

Conflicting Bisphosphonate Studies Raise Esophageal Cancer Worries

May 3, 2012 | Parker Waichman LLP
In 2010, two studies on oral bisphosphonates reached differing conclusions regarding the drugs’ association with an increased risk of esophageal cancer.  One study, published in the Journal of the American Medical (JAMA) Association, found no increased risk for esophageal cancer among patients who used oral bisphosphonates like Fosamax.  Three weeks later, the second study, which found a doubling of the risk, appeared in the British Medical Journal.Strangely enough, both...

More Bisphosphonates-Esophageal Cancer News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo